Literature DB >> 31010447

Are there temporal subtypes of premenstrual dysphoric disorder?: using group-based trajectory modeling to identify individual differences in symptom change.

Tory A Eisenlohr-Moul1, Gudrun Kaiser2, Cornelia Weise2, Katja M Schmalenberger3, Jeff Kiesner4, Beate Ditzen3, Maria Kleinstäuber5.   

Abstract

BACKGROUND: Premenstrual dysphoric disorder (PMDD) is a new Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 diagnosis characterized by the cyclical emergence of emotional and physical symptoms in the luteal phase of the menstrual cycle, with symptom remission in the follicular phase. Converging evidence highlights the possibility of distinct subtypes of PMDD with unique pathophysiologies, but temporal subgroups have yet to be explored in a systematic way.
METHODS: In the current work, we use group-based trajectory modeling to identify unique trajectory subgroups of core emotional and total PMDD symptoms across the perimenstrual frame (days -14 to +9, where day 0 is menstrual onset) in a sample of 74 individuals prospectively diagnosed with DSM-5 PMDD.
RESULTS: For the total daily symptom score, the best-fitting model was comprised of three groups: a group demonstrating moderate symptoms only in the premenstrual week (65%), a group demonstrating severe symptoms across the full 2 weeks of the luteal phase (17.5%), and a group demonstrating severe symptoms in the premenstrual week that were slow to resolve in the follicular phase (17.5%).
CONCLUSIONS: These trajectory groups are discussed in the context of the latest work on the pathophysiology of PMDD. Experimental work is needed to test for the presence of possible pathophysiologic differences in trajectory groups, and whether unique treatment approaches are needed.

Entities:  

Keywords:  Group-based trajectory modeling; menstrual cycle; premenstrual dysphoric disorder; premenstrual syndrome

Mesh:

Year:  2019        PMID: 31010447      PMCID: PMC8168625          DOI: 10.1017/S0033291719000849

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   10.592


  35 in total

Review 1.  The effectiveness of GnRHa with and without 'add-back' therapy in treating premenstrual syndrome: a meta analysis.

Authors:  Katrina M Wyatt; Paul W Dimmock; Khaled M K Ismail; Peter W Jones; P M Shaughn O'Brien
Journal:  BJOG       Date:  2004-06       Impact factor: 6.531

2.  5α-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder.

Authors:  Pedro E Martinez; David R Rubinow; Lynnette K Nieman; Deloris E Koziol; A Leslie Morrow; Crystal E Schiller; Dahima Cintron; Karla D Thompson; Khursheed K Khine; Peter J Schmidt
Journal:  Neuropsychopharmacology       Date:  2013-08-14       Impact factor: 7.853

Review 3.  Selective serotonin reuptake inhibitors and initial oral contraceptives for the treatment of PMDD: effective but not enough.

Authors:  Uriel Halbreich
Journal:  CNS Spectr       Date:  2008-07       Impact factor: 3.790

4.  Premenstrual Dysphoric Disorder Symptoms Following Ovarian Suppression: Triggered by Change in Ovarian Steroid Levels But Not Continuous Stable Levels.

Authors:  Peter J Schmidt; Pedro E Martinez; Lynnette K Nieman; Deloris E Koziol; Karla D Thompson; Linda Schenkel; Paul G Wakim; David R Rubinow
Journal:  Am J Psychiatry       Date:  2017-04-21       Impact factor: 18.112

5.  Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study.

Authors:  E W Freeman; S J Sondheimer; K Rickels
Journal:  Psychopharmacol Bull       Date:  1997

6.  Perimenstrual exacerbation of symptoms in borderline personality disorder: evidence from multilevel models and the Carolina Premenstrual Assessment Scoring System.

Authors:  Tory A Eisenlohr-Moul; Katja M Schmalenberger; Sarah A Owens; Jessica R Peters; Danyelle N Dawson; Susan S Girdler
Journal:  Psychol Med       Date:  2018-05-28       Impact factor: 7.723

7.  A specific profile of luteal phase progesterone is associated with the development of premenstrual symptoms.

Authors:  Thelma A Lovick; Vinicius G Guapo; Janete A Anselmo-Franci; Camila M Loureiro; Maria Clara M Faleiros; Cristina M Del Ben; Marcus L Brandão
Journal:  Psychoneuroendocrinology       Date:  2016-10-27       Impact factor: 4.905

8.  Pretreatment pattern of symptom expression in premenstrual dysphoric disorder.

Authors:  Teri Pearlstein; Kimberly A Yonkers; Rana Fayyad; John A Gillespie
Journal:  J Affect Disord       Date:  2005-04       Impact factor: 4.839

9.  Effects of Estradiol Withdrawal on Mood in Women With Past Perimenopausal Depression: A Randomized Clinical Trial.

Authors:  Peter J Schmidt; Rivka Ben Dor; Pedro E Martinez; Gioia M Guerrieri; Veronica L Harsh; Karla Thompson; Deloris E Koziol; Lynnette K Nieman; David R Rubinow
Journal:  JAMA Psychiatry       Date:  2015-07       Impact factor: 21.596

10.  Toward the Reliable Diagnosis of DSM-5 Premenstrual Dysphoric Disorder: The Carolina Premenstrual Assessment Scoring System (C-PASS).

Authors:  Tory A Eisenlohr-Moul; Susan S Girdler; Katja M Schmalenberger; Danyelle N Dawson; Pallavi Surana; Jacqueline L Johnson; David R Rubinow
Journal:  Am J Psychiatry       Date:  2016-08-13       Impact factor: 18.112

View more
  9 in total

Review 1.  Symptom fluctuation over the menstrual cycle in anxiety disorders, PTSD, and OCD: a systematic review.

Authors:  Saria Adele Green; Bronwyn M Graham
Journal:  Arch Womens Ment Health       Date:  2021-10-19       Impact factor: 3.633

2.  Evolution, the Menstrual Cycle, and Theoretical Overreach.

Authors:  Jeff Kiesner; Tory Eisenlohr-Moul; Jane Mendle
Journal:  Perspect Psychol Sci       Date:  2020-06-15

Review 3.  Ovarian Hormones as a Source of Fluctuating Biological Vulnerability in Borderline Personality Disorder.

Authors:  Jessica R Peters; Tory A Eisenlohr-Moul
Journal:  Curr Psychiatry Rep       Date:  2019-10-17       Impact factor: 5.285

4.  A forced swim-based rat model of premenstrual depression: effects of hormonal changes and drug intervention.

Authors:  Sheng Wei; Xiwen Geng; Zifa Li; Kaiyong Xu; Minghui Hu; Hongyun Wu; Wei Shi; Mingqi Qiao
Journal:  Aging (Albany NY)       Date:  2020-11-21       Impact factor: 5.682

Review 5.  Steroid Hormone Sensitivity in Reproductive Mood Disorders: On the Role of the GABAA Receptor Complex and Stress During Hormonal Transitions.

Authors:  Sophie Schweizer-Schubert; Jennifer L Gordon; Tory A Eisenlohr-Moul; Samantha Meltzer-Brody; Katja M Schmalenberger; Radoslaw Slopien; Anna-Lena Zietlow; Ulrike Ehlert; Beate Ditzen
Journal:  Front Med (Lausanne)       Date:  2021-01-18

6.  Trends in Research Related to Premenstrual Syndrome and Premenstrual Dysphoric Disorder From 1945 to 2018: A Bibliometric Analysis.

Authors:  Mingzhou Gao; Dongmei Gao; Hui Sun; Xunshu Cheng; Li An; Mingqi Qiao
Journal:  Front Public Health       Date:  2021-04-21

7.  Affective Risk Associated With Menstrual Cycle Symptom Change.

Authors:  Jeff Kiesner; Tory A Eisenlohr-Moul; Giulio Vidotto
Journal:  Front Glob Womens Health       Date:  2022-07-22

Review 8.  How to study the menstrual cycle: Practical tools and recommendations.

Authors:  Katja M Schmalenberger; Hafsah A Tauseef; Jordan C Barone; Sarah A Owens; Lynne Lieberman; Marc N Jarczok; Susan S Girdler; Jeff Kiesner; Beate Ditzen; Tory A Eisenlohr-Moul
Journal:  Psychoneuroendocrinology       Date:  2020-10-13       Impact factor: 4.905

9.  Resting-state functional connectivity in women with PMDD.

Authors:  Nicole Petersen; Dara G Ghahremani; Andrea J Rapkin; Steven M Berman; Noor Wijker; Letty Liang; Edythe D London
Journal:  Transl Psychiatry       Date:  2019-12-11       Impact factor: 6.222

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.